Checkpoint Therapeutics Current Ratio 2016-2021 | CKPT

Checkpoint Therapeutics current ratio from 2016 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Checkpoint Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.07B $0.01B 7.15
2021-03-31 $0.06B $0.01B 8.47
2020-12-31 $0.04B $0.01B 5.90
2020-09-30 $0.04B $0.01B 6.64
2020-06-30 $0.02B $0.01B 2.94
2020-03-31 $0.02B $0.01B 3.32
2019-12-31 $0.03B $0.01B 3.32
2019-09-30 $0.01B $0.01B 1.80
2019-06-30 $0.02B $0.01B 1.90
2019-03-31 $0.02B $0.01B 1.86
2018-12-31 $0.03B $0.01B 1.90
2018-09-30 $0.03B $0.01B 3.51
2018-06-30 $0.03B $0.01B 4.35
2018-03-31 $0.04B $0.01B 4.84
2017-12-31 $0.02B $0.01B 3.36
2017-09-30 $0.03B $0.01B 4.39
2017-06-30 $0.03B $0.00B 7.05
2017-03-31 $0.03B $0.00B 7.71
2016-12-31 $0.04B $0.00B 9.80
2016-09-30 $0.04B $0.00B 8.96
2016-06-30 $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.284B $0.001B
Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71